Drug Profile
IDPS
Latest Information Update: 09 Jan 2008
Price :
$50
*
At a glance
- Originator Hollis-Eden Pharmaceuticals
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 31 May 1999 New profile
- 31 May 1999 Preclinical development for Transplant rejection in USA (Unknown route)